Trials / Completed
CompletedNCT02070965
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Randomized Parallel Group Open-Label Multicenter Study to Assess the Potential for Adrenal Supp and Syst Drug Abs Following Multi Dosing With DFD-01 (Betamethasone Dipropionate) Spray 0.05% in Adol Subjects With Mod to Sev Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Primus Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DFD01 Spray | |
| DRUG | Comp01 Lotion |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2014-02-25
- Last updated
- 2024-03-07
- Results posted
- 2017-03-13
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02070965. Inclusion in this directory is not an endorsement.